Wilms' Tumour (Nephroblastoma)

1. Clinical Overview

Summary

Wilms' Tumour (Nephroblastoma) is the most common primary renal malignancy of childhood, accounting for approximately 90% of paediatric kidney cancers. It arises from embryonic kidney tissue (metanephric blastema) that failed to differentiate normally during fetal development. The tumour typically presents in children aged 2-5 years with a painless, smooth, unilateral abdominal mass that does NOT cross the midline – a critical differentiating feature from neuroblastoma. [1,2]

The condition has an excellent prognosis with modern multimodal therapy, achieving 5-year survival rates exceeding 90% for localised disease. Treatment involves a coordinated approach of chemotherapy, surgery, and radiotherapy tailored to disease stage and histology. Approximately 5-10% of cases are bilateral at presentation, requiring nephron-sparing surgical approaches. [3,4]

Wilms' tumour is associated with several genetic syndromes including WAGR syndrome (Wilms, Aniridia, Genitourinary malformations, intellectual disability), Beckwith-Wiedemann syndrome, and Denys-Drash syndrome, all requiring heightened surveillance. The discovery of tumour suppressor genes WT1 (11p13) and WT2 (11p15) has revolutionised understanding of nephroblastoma pathogenesis. [5,6]

Clinical Pearls

Does NOT Cross the Midline: Wilms' tumour is intrarenal in origin and typically remains confined to one side of the abdomen. This contrasts with neuroblastoma (adrenal/sympathetic chain origin), which frequently crosses the midline and engulfs major vessels. This single examination finding is often the key discriminator in clinical assessments.

"Cannonball" Lung Metastases: Wilms' tumour spreads haematogenously, with lungs being the most common metastatic site (85% of metastatic cases). Chest radiography shows characteristic large, round, well-circumscribed lesions resembling cannonballs – a pathognomonic radiological finding that should prompt immediate paediatric oncology referral. [7]

DO NOT RUPTURE THE TUMOUR: Intraoperative tumour rupture is catastrophic, upstaging disease from Stage I/II to Stage III and significantly worsening prognosis. This necessitates flank radiotherapy and more intensive chemotherapy. The SIOP (European) protocol uses pre-operative chemotherapy to shrink tumours and reduce rupture risk, whereas the COG (North American) protocol prioritises upfront nephrectomy for accurate histological staging. [8]

Aniridia = Screen for Wilms': Congenital absence of the iris (aniridia) should trigger immediate genetic evaluation for WAGR syndrome (WT1 deletion). These children have a 30-50% lifetime risk of developing Wilms' tumour, requiring 3-monthly renal ultrasound surveillance from birth until age 7 years. This represents one of the highest cancer predisposition risks in paediatrics. [9]

Bilateral Disease Requires Nephron-Sparing Surgery: Stage V Wilms' tumour (bilateral disease at diagnosis) presents unique challenges. The goal is cancer cure whilst preserving maximal renal tissue to avoid dialysis dependency. Treatment involves pre-operative chemotherapy to shrink tumours, followed by bilateral partial nephrectomies (nephron-sparing surgery) rather than bilateral total nephrectomy. [10]

---

2. Epidemiology

Demographics and Incidence

Wilms' tumour demonstrates characteristic epidemiological patterns that aid clinical recognition and risk stratification:

Age Distribution

The age at presentation differs significantly between unilateral and bilateral cases:

• Unilateral Wilms': Median age 3.5 years (range 6 months - 15 years)
• Bilateral Wilms': Median age 2.5 years (typically younger presentation) [3]
• Syndromic Wilms': Often earlier presentation (median 2 years)
• Anaplastic Histology: Tends to present in older children (median 5 years)

Exam Detail: MRCPCH High-Yield: Wilms' tumour presenting after age 10 years is unusual and should prompt consideration of alternative diagnoses (renal cell carcinoma, clear cell sarcoma, rhabdoid tumour) or unfavourable histology subtypes. Late presentation is associated with worse prognosis.

Associated Genetic Syndromes

Approximately 10-15% of Wilms' tumours occur in the context of hereditary cancer predisposition syndromes. Recognition is critical for surveillance and genetic counselling:

Clinical Pearl: Aniridia at birth: Any newborn with congenital aniridia requires immediate ophthalmology review, genetic testing for WT1 deletion, and initiation of renal tumour surveillance. The presence of aniridia alone (even without other WAGR features) mandates screening due to the high WT1 deletion rate.

Geographic and Ethnic Patterns

• African Ancestry: 2-fold higher incidence compared to European children; earlier age at diagnosis [11]
• Asian Populations: Lower incidence (approximately 50% that of European children)
• Socioeconomic Factors: No consistent association with socioeconomic status
• Environmental Factors: No established environmental risk factors (unlike many adult cancers)

---

3. Aetiology and Pathophysiology

Molecular Pathogenesis

Wilms' tumour arises from disruption of normal kidney development during embryogenesis. Understanding this pathogenesis is essential for MRCPCH examination success:

Normal Kidney Development (Recap)

1. Week 5 of Gestation: Metanephric blastema (embryonic kidney precursor cells) interacts with ureteric bud
2. Weeks 6-36: Blastema differentiates into nephrons (glomeruli, tubules, stroma)
3. Birth: Kidney contains ~1 million nephrons; no further nephron formation occurs postnatally

Nephrogenic Rests and Tumorigenesis

Nephrogenic rests are foci of persistent embryonic kidney tissue that failed to differentiate or involute. These are found in:

• 1% of infant autopsies (normal finding)
• 30-40% of unilateral Wilms' tumour cases (adjacent to tumour)
• Nearly 100% of bilateral Wilms' tumour cases [14]

Rests are classified by location:

• Perilobar Nephrogenic Rests (PLNR): Located at kidney periphery; associated with BWS, sporadic bilateral Wilms'
• Intralobar Nephrogenic Rests (ILNR): Within kidney parenchyma; associated with WAGR, Denys-Drash, familial cases

Exam Detail: Viva Question: "Why do children with bilateral Wilms' require lifelong surveillance even after successful treatment?"

Model Answer: Bilateral Wilms' tumour indicates a field defect with diffuse nephrogenic rests throughout both kidneys. Even after complete tumour resection, residual rests have malignant potential. Additionally, these patients often have germline WT1 mutations, conferring lifelong increased cancer risk. Surveillance includes annual renal ultrasound and monitoring for late relapse or second malignancies.

Tumour Suppressor Genes

WT1 Gene (Chromosome 11p13)

The WT1 gene encodes a zinc-finger transcription factor crucial for urogenital development:

• Function: Regulates genes involved in kidney and gonad development
• Expression: High in metanephric blastema during nephrogenesis; downregulated as differentiation occurs
• Mutations: Found in 10-20% of sporadic Wilms' tumours [5]
• Germline WT1 mutations: WAGR, Denys-Drash, Frasier syndromes

Two-Hit Hypothesis: Knudson's model applies:

1. First hit: Germline WT1 mutation (inherited or de novo) → predisposition
2. Second hit: Somatic mutation in remaining allele → tumour formation

This explains:

• Early age at diagnosis in syndromic cases (only need one somatic hit)
• Bilateral/multifocal tumours in germline mutation carriers
• Later diagnosis in sporadic cases (require two somatic hits)

WT2 Locus (Chromosome 11p15)

The 11p15 region contains imprinted genes critical for growth regulation:

• IGF2 (insulin-like growth factor 2): Paternally expressed growth promoter
• H19: Maternally expressed growth suppressor
• CDKN1C (p57): Maternally expressed cell cycle inhibitor

Loss of Imprinting (LOI): Most common molecular abnormality in Wilms' tumour

• Biallelic IGF2 expression (normally only paternal allele expressed) → growth advantage
• Loss of H19 expression → loss of growth suppression
• Found in 70% of Wilms' tumours [15]

This mechanism underlies Beckwith-Wiedemann syndrome:

• Paternal uniparental disomy of 11p15
• Maternal allele deletions
• Imprinting centre defects

Other Genetic Alterations

Clinical Pearl: TP53 mutations and anaplasia: Detection of TP53 mutations in Wilms' tumour is clinically significant. These tumours show anaplastic histology (large, hyperchromatic nuclei with abnormal mitoses), are chemotherapy-resistant, and have significantly worse prognosis (5-year survival 40-70% vs > 90% for favourable histology). TP53 mutation testing may guide intensification of therapy. [16]

Histopathology

Classic Wilms' tumour demonstrates triphasic histology – an attempt by embryonic cells to recapitulate normal kidney development:

1. Blastemal Component

• Small, round, blue cells (primitive, undifferentiated)
• High nuclear:cytoplasmic ratio
• Resembles metanephric blastema of early kidney development

2. Stromal Component

• Spindle cells, fibroblasts
• May contain heterologous elements: skeletal muscle, cartilage, fat, bone

3. Epithelial Component

• Tubular structures (attempting to form primitive nephrons)
• Glomeruloid bodies (attempting to form glomeruli)
• Variable differentiation

Blastemal-predominant tumours (after chemotherapy) indicate chemotherapy resistance and may require treatment intensification.

Favourable vs Unfavourable Histology

This distinction is critical for prognosis and treatment stratification:

Exam Detail: MRCPCH Data Interpretation Station: You are shown histology slides with the following features – large cells with nuclei 3 times normal size, hyperchromatic, with multipolar mitotic figures scattered throughout the specimen.

Question: What is the histological classification, and how does this affect management?

Answer: This describes diffuse anaplastic Wilms' tumour (unfavourable histology). Anaplasia is present in > 10% of tumour volume. Management implications:

1. Significantly worse prognosis (5-year survival 30-70% depending on stage vs > 90% for favourable)
2. Requires intensified chemotherapy regimen (addition of cyclophosphamide, etoposide, carboplatin)
3. Lower threshold for radiotherapy (often given for Stage II anaplastic disease)
4. Increased risk of relapse and metastases
5. May consider experimental therapies or clinical trial enrollment

Patterns of Spread

Understanding metastatic patterns guides staging investigations:

---

4. Clinical Presentation

History

The clinical presentation of Wilms' tumour is often subtle, with most children appearing systemically well despite harboring a large abdominal mass.

Presenting Symptoms (by frequency)

Clinical Pearl: "Too well for neuroblastoma": A classic teaching point is that children with Wilms' tumour typically appear well and thriving despite a massive abdominal mass, whereas children with neuroblastoma often appear systemically unwell with weight loss, pallor, and irritability. This clinical gestalt can guide initial differential diagnosis.

History-Taking Focus Areas (OSCE/MRCPCH Clinical)

When taking a history for suspected Wilms' tumour, systematically explore:

1. Mass Discovery: When? Who noticed? How? Growing?
2. Urinary Symptoms: Haematuria (colour of urine), dysuria, frequency
3. Systemic Symptoms: Fever, sweats, weight loss, appetite, energy
4. Abdominal Symptoms: Pain (site, character, radiation), distension, vomiting
5. Family History: Wilms' tumour (familial cases 1-2%), other childhood cancers
6. Syndrome Features (systematic enquiry):
   • Vision/Eyes: Aniridia, strabismus (WAGR)
   • Genitourinary: Hypospadias, undescended testes, previous genital surgery (WAGR, Denys-Drash)
   • Growth: Macrosomia at birth, hemihypertrophy, asymmetric limb growth (BWS)
   • Development: Developmental delay, intellectual disability (WAGR, Perlman)
   • Neonatal: Hypoglycaemia, exomphalos/omphalocele (BWS)
7. Birth History: Birthweight (> 4kg suggests BWS), gestational age, neonatal issues

Examination Findings

A systematic approach to examining a child with suspected Wilms' tumour is essential for MRCPCH clinical examinations.

General Inspection

• Appearance: Usually well-appearing, playful, appropriate affect
• Growth: Plot height/weight on centile charts
  • "Macrosomia (> 97th centile): Beckwith-Wiedemann"
  • "Short stature (less than 3rd centile): Bloom syndrome"
• Dysmorphic Features: Coarse facies, hemihypertrophy, ear abnormalities

Abdominal Examination

Inspection:

• Visible asymmetry (flank fullness on affected side)
• Abdominal distension
• Visible veins (IVC obstruction)
• Previous surgical scars

Palpation (perform gently to avoid tumour rupture):

• Location: Arises from flank (renal angle)
• Size: May be massive (10-20 cm diameter)
• Shape: Smooth, rounded (not irregular like neuroblastoma)
• Consistency: Firm, solid
• Midline: Does NOT cross midline (critical sign) [2]
• Mobility: Limited (retroperitoneal)
• Ballotable: May be ballotable (kidney is retroperitoneal)
• Tenderness: Usually non-tender

Percussion:

• Dull to percussion (solid mass)
• Bowel sounds present (mass is retroperitoneal, not displacing bowel completely)

Auscultation:

• Renal bruit (rare, if renal artery stenosis from tumour compression)

Exam Detail: OSCE Examination Technique: When examining a child's abdomen for suspected renal mass:

1. Position: Child supine, relaxed, parent present
2. Warm hands: Essential for child cooperation
3. Start away from mass: Begin palpation in normal quadrants
4. Two-handed bimanual palpation: One hand in flank (posteriorly), one hand anteriorly
5. Assess for "crossing midline": Palpate from lateral to medial, defining medial edge
6. Ballottement test: Attempt to "bounce" mass between hands (suggests retroperitoneal)
7. Complete examination: Don't forget to examine other side, genitalia, blood pressure

Examiner Question: "What is the significance of a mass that does NOT cross the midline?"

Answer: A mass that does not cross the midline suggests renal origin (Wilms' tumour, hydronephrosis) rather than neuroblastoma. Neuroblastoma arises from adrenal gland or sympathetic chain, grows across the midline, and engulfs the aorta and IVC. Wilms' tumour is intrarenal, remains confined by renal fascia, and displaces vessels rather than encasing them.

Specific Syndrome Screening

Blood Pressure Measurement

Critical in Wilms' tumour assessment:

• Frequency: 25% have hypertension at diagnosis [18]
• Mechanism: Renin secretion by tumour or compression of renal artery
• Technique: Age-appropriate cuff (bladder width = 40% of arm circumference)
• Interpretation: Use age/height-specific centile charts
• Complications: Hypertensive encephalopathy, seizures (medical emergency)

---

5. Differential Diagnosis

The differential diagnosis of a paediatric abdominal mass is broad. Systematic clinical and radiological assessment is required.

Paediatric Abdominal Mass Differential

Wilms' Tumour vs Neuroblastoma (High-Yield Comparison)

This distinction is a classic MRCPCH examination question and crucial for clinical practice:

Clinical Pearl: "Raccoon Eyes": Periorbital ecchymoses (bruising around both eyes without direct trauma) is a pathognomonic sign of metastatic neuroblastoma with orbital involvement. This should never be attributed to trauma or non-accidental injury without thorough investigation including urinary catecholamines and abdominal imaging.

Rare Renal Tumours of Childhood

While Wilms' tumour accounts for 90% of paediatric renal tumours, awareness of rarer entities is important for MRCPCH:

Clear Cell Sarcoma of Kidney (CCSK)

• 3-5% of paediatric renal tumours
• Age 2-4 years (similar to Wilms')
• Characteristic: Propensity for bone metastases (unlike Wilms' which goes to lungs)
• Histology: Uniform "clear cells" with chicken-wire vascular pattern
• Poorer prognosis than Wilms' (70-80% 5-year survival)
• Requires more intensive chemotherapy (addition of doxorubicin mandatory)

Rhabdoid Tumour of Kidney (RTK)

• 2% of paediatric renal tumours
• Age less than 2 years (median 11 months) – very young
• Most aggressive paediatric renal malignancy
• Often metastatic at diagnosis (lungs, brain)
• Associated with SMARCB1/INI1 gene mutations (chromosome 22q11)
• Synchronous brain tumours (atypical teratoid/rhabdoid tumour) in 10-15%
• Prognosis: Very poor (5-year survival less than 30%) despite intensive therapy
• Hypercalcaemia may be present (paraneoplastic)

Congenital Mesoblastic Nephroma (CMN)

• Most common renal tumour in neonates and infants less than 6 months
• Benign or low malignant potential
• Presentation: Abdominal mass, hypercalcaemia, polyhydramnios (antenatal diagnosis)
• Treatment: Surgical excision (usually curative without chemotherapy)
• Excellent prognosis (> 95% cure with complete resection)

Exam Detail: Viva Scenario: "A 3-month-old infant presents with a large renal mass identified on antenatal ultrasound. The family is worried it is Wilms' tumour. How do you counsel them?"

Model Answer: "Wilms' tumour is very rare at this age (peak 2-5 years). In a 3-month-old with a renal mass, the most likely diagnosis is congenital mesoblastic nephroma, which is benign or low-grade. I would explain that:

1. This is likely a benign tumour requiring only surgical removal
2. Chemotherapy is usually not needed
3. Prognosis is excellent with complete excision
4. We will perform imaging (USS/MRI) and surgical excision with histology to confirm
5. Post-operative surveillance is minimal compared to Wilms'
6. The family can be reassured this is not the same as Wilms' tumour in older children"

---

6. Investigations

Initial Assessment (Emergency Department/Primary Care)

When a child presents with a suspected abdominal mass, initial investigations aim to:

1. Confirm presence of mass (imaging)
2. Differentiate Wilms' from neuroblastoma (urinary catecholamines)
3. Assess systemic involvement (basic bloods, CXR)

First-Line Investigations

Clinical Pearl: Urinary Catecholamine Collection: For accurate VMA/HVA measurement, a 24-hour urine collection is ideal but impractical in young children. A spot urine VMA/HVA:creatinine ratio is acceptable. Avoid foods that interfere with assay (bananas, vanilla, coffee) for 48 hours before collection. Normal values effectively rule out neuroblastoma.

Imaging

Imaging is central to diagnosis, staging, and surgical planning. All imaging should be performed before biopsy to avoid tumour seeding.

Abdominal Ultrasound (First-Line)

Indications: All children with suspected abdominal mass

Advantages:

• Non-invasive, no radiation, no sedation required
• Excellent for differentiating solid vs cystic masses
• Real-time assessment of IVC for tumour thrombus

Ultrasound Findings in Wilms' Tumour:

• Intrarenal origin: Mass arises from within kidney parenchyma
• Solid, heterogeneous mass: Mixed echogenicity (areas of necrosis, haemorrhage)
• "Claw Sign": Rim of normal kidney tissue surrounding tumour (confirms renal origin) [20]
• Contralateral kidney: Assess for bilateral disease, nephrogenic rests
• Renal vein/IVC: Tumour thrombus extension (present in 5-10%)
• Liver: Assess for metastases
• Ascites: Suggests peritoneal involvement or rupture

Exam Detail: Radiology Interpretation Station: You are shown an ultrasound image demonstrating a large heterogeneous mass within the right kidney with a thin rim of normal renal tissue surrounding it.

Question: What is this radiological sign called, and what is its significance?

Answer: This is the "claw sign" – normal renal parenchyma "clawing" around a mass, confirming intrarenal origin. This distinguishes Wilms' tumour (intrarenal) from neuroblastoma (extrarenal, displacing kidney). The claw sign is highly specific for renal origin and guides surgical planning by confirming the mass is within the kidney requiring nephrectomy.

CT Abdomen and Pelvis (Staging)

Indications: Staging once Wilms' tumour diagnosed

Protocol: Contrast-enhanced CT (arterial and venous phases)

CT Findings and Staging Information:

• Tumour size and extent: Precise measurements for surgical planning
• Intrarenal vs extrarenal extension: Capsular breach upstages disease
• Lymph nodes: Enlarged nodes (> 1cm) suggest Stage III [8]
• Renal vein/IVC thrombus: Extension to right atrium requires cardiothoracic involvement [17]
• Contralateral kidney: Synchronous bilateral disease (Stage V)
• Liver metastases: Stage IV disease
• Peritoneal disease: Tumour rupture, ascites

MRI Abdomen (Alternative to CT)

Indications:

• Superior soft tissue contrast (delineate tumour from normal kidney)
• IVC thrombus characterisation (distinguish tumour thrombus from bland thrombus)
• Avoid radiation (especially in syndromic children requiring lifelong surveillance)
• Pre-operative planning for nephron-sparing surgery (bilateral disease)

Advantages over CT:

• No ionising radiation
• Better soft tissue contrast
• Multiplanar imaging (coronal, sagittal planes useful for surgical planning)

Disadvantages:

• Requires sedation/general anaesthesia in young children
• Longer acquisition time
• Less available than CT

Chest Imaging (Metastases Screening)

Chest X-Ray (CXR):

• First-line for pulmonary metastases screening
• "Cannonball" lesions: Large, round, well-circumscribed nodules in lungs [7]
• Sensitivity ~70% (misses small metastases)

CT Chest (High-Resolution):

• Indications: Abnormal CXR OR for accurate staging even if CXR normal
• Detects lung metastases less than 5mm (not visible on CXR)
• Approximately 10% of "CXR-negative" patients have lung metastases on CT
• CT-only metastases (CXR-negative): Management controversial – some protocols treat as Stage I, others as Stage IV

Exam Detail: Evidence-Based Discussion: The COG (Children's Oncology Group) and SIOP (International Society of Paediatric Oncology) protocols differ in how they manage CT-only lung nodules:

• COG approach: CT-only nodules that resolve with chemotherapy are considered Stage I (favourable)
• SIOP approach: Any lung nodules (CXR or CT detected) constitute Stage IV

This reflects differing philosophies on treatment intensification. MRCPCH candidates should be aware that international protocols exist and clinical practice may vary.

Specialised Imaging

Biopsy

Percutaneous biopsy is generally CONTRAINDICATED in suspected Wilms' tumour due to:

1. Risk of tumour rupture and peritoneal seeding
2. Upstaging from Stage I/II to Stage III
3. Risk of bleeding
4. Diagnosis usually made on imaging + clinical context

Exceptions (biopsy may be considered):

• Bilateral disease (to confirm histology before nephron-sparing surgery)
• Diagnostic uncertainty (cannot differentiate from other renal tumours)
• Inoperable disease requiring neoadjuvant chemotherapy and histological confirmation

---

7. Staging

Two major staging systems exist: COG (Children's Oncology Group, North America) and SIOP (International Society of Paediatric Oncology, Europe/UK). The key difference is timing of surgery:

• COG: Upfront surgery → staging based on surgical pathology
• SIOP: Pre-operative chemotherapy → surgery → staging based on post-chemotherapy pathology

COG Staging System (Post-Surgical, No Pre-Op Chemotherapy)

SIOP Staging System (Post-Chemotherapy)

Similar stages but based on pathology after pre-operative chemotherapy:

• Stage I: Tumour confined to kidney, completely excised (post-chemotherapy)
• Stage II: Tumour extends beyond kidney but completely excised
• Stage III: Incomplete excision, lymph node involvement, peritoneal contamination, or rupture
• Stage IV: Haematogenous metastases
• Stage V: Bilateral disease

Clinical Pearl: Why do stages differ between protocols? Pre-operative chemotherapy (SIOP) shrinks tumours, making them easier to resect completely and reducing rupture risk. This results in "stage migration" – tumours that would be Stage III with upfront surgery may be Stage I after chemotherapy. This does NOT mean SIOP children have better outcomes; it reflects different staging timing. Long-term survival rates are comparable between protocols.

Histological Risk Stratification (SIOP)

SIOP further stratifies by histological risk after pre-operative chemotherapy:

Blastemal-predominant tumours after chemotherapy indicate chemotherapy resistance and require treatment intensification.

---

8. Management

Management of Wilms' tumour requires multidisciplinary collaboration between paediatric oncology, paediatric surgery, radiology, pathology, and supportive care teams. Treatment is risk-stratified based on stage and histology.

Treatment Protocols: SIOP vs COG

The two major international protocols differ in surgical timing:

Exam Detail: Viva Question: "What are the advantages and disadvantages of pre-operative chemotherapy in Wilms' tumour?"

Model Answer:

Advantages:

1. Tumour shrinkage makes surgical resection easier and safer
2. Reduced tumour rupture rate (5% vs 15% with upfront surgery) [8]
3. May downstage disease, reducing need for radiotherapy
4. Allows assessment of chemotherapy response (blastemal predominance indicates resistance)

Disadvantages:

1. Histology altered by chemotherapy – cannot assess true biological behaviour
2. Delays definitive histological diagnosis
3. Risk of treating benign lesions (e.g., mesoblastic nephroma) with chemotherapy
4. Rare possibility of tumour progression during pre-operative chemotherapy

Clinical Context: SIOP protocol is standard in UK/Europe; COG protocol in North America. Both achieve similar excellent survival rates (> 90%), reflecting different but equally valid approaches.

Surgical Management

Radical Nephrectomy (Unilateral Disease)

Procedure:

• Complete removal of affected kidney, ureter (down to bladder), ipsilateral adrenal gland (if involved)
• Regional lymph node sampling (minimum 7 nodes for accurate staging)
• Examination of contralateral kidney (bimanual palpation)
• Vascular ligation before manipulation (reduce tumour cell shedding)

Surgical Principles:

1. Avoid tumour rupture (upstages to Stage III, worsens prognosis) [8]
2. Achieve clear margins (R0 resection)
3. Sample lymph nodes (positive nodes = Stage III)
4. Inspect contralateral kidney (5-10% have bilateral disease)
5. Assess tumour thrombus (extend incision/sternotomy if IVC thrombus to right atrium) [17]

Clinical Pearl: Intraoperative tumour rupture is a surgical emergency requiring immediate oncology consultation. The peritoneal cavity should be irrigated, spillage documented precisely, and clips placed to mark areas of contamination. Post-operative management includes:

• Upstaging to Stage III (even if otherwise Stage I)
• Addition of flank/abdominal radiotherapy
• Intensified chemotherapy
• Increased surveillance for peritoneal recurrence

Nephron-Sparing Surgery (Bilateral Disease, Stage V)

Indications:

• Bilateral Wilms' tumour (Stage V)
• Unilateral Wilms' in child with pre-existing renal impairment
• Unilateral Wilms' with syndrome predisposing to future contralateral Wilms' (e.g., WAGR)

Approach:

1. Pre-operative chemotherapy (12 weeks) to shrink tumours maximally
2. Bilateral partial nephrectomy: Remove tumour whilst preserving maximal normal renal tissue
3. Goal: Avoid dialysis dependency
4. Outcome: 70-80% maintain renal function off dialysis at 5 years [10]

Challenges:

• Higher local recurrence rate (5-10% vs less than 2% for radical nephrectomy)
• Requires expert paediatric surgical/urological input
• Balancing oncological clearance with renal preservation

Chemotherapy

Chemotherapy is the cornerstone of Wilms' tumour treatment, used both pre-operatively (SIOP) and post-operatively (COG and SIOP).

Standard Chemotherapy Agents

Intensified Chemotherapy (High-Risk Disease)

For anaplastic histology, Stage IV, or relapsed disease:

Chemotherapy Regimens by Stage (SIOP Protocol)

Exam Detail: MRCPCH Clinical Scenario: A 4-year-old with Stage III intermediate-risk Wilms' tumour (lymph node involvement) has received 18 weeks of chemotherapy (vincristine, actinomycin D, doxorubicin). Parents ask about long-term side effects of treatment.

Answer: I would counsel the parents about:

Immediate Side Effects (during treatment):

• Myelosuppression: Risk of infection, bleeding, anaemia
• Nausea and vomiting: Manageable with anti-emetics
• Hair loss (doxorubicin): Temporary, regrows post-treatment
• Peripheral neuropathy (vincristine): Numbness, constipation, jaw pain

Long-Term Effects (requiring lifelong surveillance):

1. Cardiac: Doxorubicin cardiotoxicity – cumulative dose-dependent. Requires echocardiography at end of treatment, then 2-yearly lifelong. Risk of heart failure, cardiomyopathy in adulthood.
2. Renal: Single kidney – lifelong monitoring of renal function, BP. Advise avoid nephrotoxic drugs, contact sports with risk of kidney injury.
3. Secondary Malignancies: Small increased risk (2-3%) of second cancers in adulthood due to chemotherapy + radiotherapy (if given).
4. Fertility: Generally preserved with these agents, but discuss fertility preservation pre-treatment if intensified therapy planned.
5. Growth: Potential growth impairment if spinal radiotherapy given (not standard for Stage III).
6. Educational/Developmental: Missed schooling, psychosocial impact – arrange education support.

Regular long-term follow-up in paediatric oncology late-effects clinic is essential.

Radiotherapy

Radiotherapy is reserved for higher-stage or high-risk disease due to long-term growth and developmental effects in children.

Indications for Radiotherapy

Long-Term Effects of Radiotherapy

• Musculoskeletal: Scoliosis, hypoplasia of radiated bones, limb length discrepancy
• Organ Dysfunction: Radiation nephritis (contralateral kidney), hepatotoxicity, bowel strictures
• Secondary Malignancies: Increased risk of sarcomas, carcinomas in radiation field (2-3% at 20 years)
• Reproductive: Ovarian failure (if pelvic radiation), reduced fertility

Clinical Pearl: Omitting radiotherapy when possible: Modern risk-stratified protocols aim to omit radiotherapy for favourable-histology Stage I-II disease, relying on surgery + chemotherapy alone. This reduces long-term morbidity whilst maintaining excellent survival. Stage III disease still requires radiotherapy for local control.

---

9. Complications

Complications of Disease

Complications of Treatment

Surgical Complications

Chemotherapy Complications

Radiotherapy Complications

• Acute: Skin erythema, diarrhoea, fatigue
• Late: Scoliosis, second malignancies, organ dysfunction (see above)

Late Effects and Long-Term Surveillance

All Wilms' tumour survivors require lifelong follow-up in paediatric/adult late-effects clinics:

Exam Detail: Long-Term Follow-Up Protocol (UK Guidelines):

Years 0-5 post-treatment:

• Every 3 months: Clinical examination, BP, urinalysis
• Annually: FBC, U&Es, LFTs, echocardiography (if doxorubicin), CXR

Years 5-10 post-treatment:

• Every 6 months: Clinical examination, BP, urinalysis
• Annually: U&Es, echocardiography

> 10 years post-treatment:

• Annual review in late-effects clinic
• Transition to adult late-effects service
• Lifelong surveillance for cardiac, renal, second malignancies

Red Flags for Relapse: New abdominal mass, haematuria, respiratory symptoms (lung mets), bone pain. Most relapses occur within 2 years of treatment completion.

---

10. Prognosis and Outcomes

Wilms' tumour is one of the most curable childhood cancers, with overall 5-year survival exceeding 90% in high-income countries. Prognosis depends on stage, histology, and age.

Survival by Stage and Histology

Clinical Pearl: Anaplastic histology is the most important adverse prognostic factor. Diffuse anaplasia (> 10% of tumour) confers 5-year survival of only 30-50% even for early-stage disease, compared to > 95% for favourable histology. This is due to TP53 mutations conferring chemotherapy resistance. [16]

Prognostic Factors

Relapse

• Frequency: 10-15% overall (varies by stage/histology)
• Timing: 80% of relapses occur within 2 years of treatment completion
• Sites: Lungs (50%), abdomen/tumour bed (30%), liver, brain, bone
• Salvage Treatment: Relapsed Wilms' tumour is challenging but potentially curable:
  • "Relapse after favourable-histology Wilms': 50-60% long-term survival with salvage therapy"
  • "Relapse after anaplastic Wilms': less than 20% long-term survival"
  • "Salvage regimen: Intensive chemotherapy (ifosfamide, carboplatin, etoposide) + surgery + radiotherapy"

Exam Detail: Viva Question: "A 6-year-old child treated for Stage II favourable-histology Wilms' tumour 18 months ago presents with new lung nodules on surveillance CXR. What is your management approach?"

Model Answer:

Diagnosis: Suspected pulmonary relapse of Wilms' tumour.

Investigations:

1. CT chest (confirm and characterise nodules)
2. CT abdomen (assess for local recurrence)
3. Biopsy of accessible lung nodule (confirm relapse vs second malignancy vs infection)
4. FBC, U&Es, LFTs (baseline for salvage chemotherapy)

Management:

1. MDT discussion (paediatric oncology, thoracic surgery, radiology)
2. Salvage chemotherapy: Intensive regimen (e.g., ICE protocol: ifosfamide, carboplatin, etoposide)
3. Surgery: Metastasectomy (lung nodule resection) if feasible and limited disease
4. Radiotherapy: Whole-lung irradiation if multiple bilateral nodules
5. Psychosocial support: Relapsed cancer diagnosis is devastating for family; involve psychologist

Prognosis: Relapsed favourable-histology Wilms' has 50-60% salvage rate with aggressive multimodal therapy. Early detection through surveillance imaging improves outcomes.

Late Mortality

Even decades after successful treatment, survivors face risks:

• Second Malignancies: 2-3% cumulative incidence at 20 years (sarcomas, breast cancer, leukaemia)
• Cardiovascular Disease: Doxorubicin-related cardiomyopathy may manifest in adulthood
• Renal Failure: Chronic kidney disease from single kidney, radiation, chemotherapy

Standardised Mortality Ratio (SMR): Wilms' tumour survivors have SMR of 8-10 (8-10 times higher mortality than age-matched population), primarily due to treatment-related late effects.

---

11. Evidence and Guidelines

Key Guidelines

Landmark Trials

SIOP Trials

COG Trials

Exam Detail: Evidence-Based Medicine Question: "What is the evidence for pre-operative chemotherapy in Wilms' tumour?"

Answer:

Evidence FOR pre-operative chemotherapy (SIOP approach):

1. Reduced tumour rupture: SIOP-WT 2001 trial showed rupture rate 5% (SIOP) vs 15% (COG) [8]
2. Easier surgery: Tumour shrinkage facilitates complete resection
3. Reduced Stage III disease: Downstaging reduces need for radiotherapy
4. Chemotherapy response assessment: Identifies blastemal-predominant tumours (resistance)

Evidence AGAINST (concerns):

1. Histology alteration: Cannot assess true biological behaviour (pre-treatment histology unknown)
2. Overtreatment risk: Benign lesions (mesoblastic nephroma) receive chemotherapy
3. Delays diagnosis: Rare reports of tumour progression during pre-operative chemotherapy

Conclusion: Both SIOP (pre-operative chemo) and COG (upfront surgery) protocols achieve equivalent excellent survival (> 90%), demonstrating two valid approaches. Choice depends on regional practice and institutional expertise. SIOP is standard in UK/Europe.

---

12. Patient and Layperson Explanation

What is Wilms' Tumour?

Wilms' tumour, also called nephroblastoma, is a type of kidney cancer that affects young children. It is the most common kidney cancer in children, usually diagnosed between ages 2 and 5 years.

The tumour grows from cells that were meant to become normal kidney tissue before birth but didn't develop properly. These cells start growing out of control, forming a lump (tumour) in the kidney.

How Common is It?

Wilms' tumour affects about 1 in 10,000 children. In the UK, around 80-90 children are diagnosed each year. It is one of the most curable childhood cancers – more than 9 out of 10 children (90%) are cured with treatment.

What Are the Symptoms?

Most children with Wilms' tumour are otherwise healthy and active. Common signs include:

• Lump in the tummy (abdomen): Usually noticed by a parent during bathing or nappy changing
• Tummy pain or swelling
• Blood in urine (may be pink or red)
• High blood pressure (may cause headaches or irritability)
• Fever (less common)

Many children have no symptoms, and the tumour is found during a routine check-up or examination for another reason.

How is It Diagnosed?

If a doctor suspects Wilms' tumour, your child will have:

1. Ultrasound scan (like pregnancy scans): Painless scan using sound waves to see the kidneys
2. CT or MRI scan: Detailed pictures to see the size of the tumour and check if it has spread
3. Urine test: To check for signs of kidney problems
4. Blood tests: To check kidney function and overall health
5. Chest X-ray: To check the lungs (cancer can spread to lungs)

How is It Treated?

Treatment for Wilms' tumour is very effective and usually includes:

1. Chemotherapy (Cancer Medicine)

• What it is: Strong medicines that kill cancer cells
• When given:
  • In the UK, chemotherapy is usually given before surgery (for 4-6 weeks) to shrink the tumour
  • More chemotherapy is given after surgery to kill any remaining cancer cells
• How given: Through a small tube (cannula) in a vein or through a "central line" (special tube placed in a large vein)
• Side effects: Hair loss (temporary), feeling sick, increased risk of infections (medicine affects immune system)

2. Surgery

• What happens: The surgeon removes the kidney containing the cancer
• Living with one kidney: Children (and adults) can live completely normal, healthy lives with one kidney. The remaining kidney grows larger and does the work of two.
• Recovery: Usually 5-7 days in hospital, then 4-6 weeks recovery at home

3. Radiotherapy (Sometimes Needed)

• What it is: High-energy X-rays that kill cancer cells
• When needed: If the cancer has spread to lymph nodes, if the tumour ruptured during surgery, or if cancer has spread to other parts of the body
• How given: Painless treatment, like having an X-ray, for a few minutes each day for several weeks

What Are the Chances of Cure?

Wilms' tumour is one of the most curable childhood cancers. The chances of cure depend on the "stage" (how far the cancer has spread):

• If cancer is just in the kidney (most children): Over 95% are cured
• If cancer has spread to nearby lymph nodes: 85-90% are cured
• If cancer has spread to the lungs: 75-85% are cured

What Happens After Treatment?

After treatment finishes, your child will have regular check-ups to:

• Make sure the cancer doesn't come back (most likely in the first 2 years)
• Check the remaining kidney is working well
• Check for any long-term effects from treatment (heart, growth)

Follow-up schedule (typical):

• First 2 years: Every 3 months
• Years 2-5: Every 6 months
• After 5 years: Once a year

Will My Child Lead a Normal Life?

Yes! Most children treated for Wilms' tumour go on to:

• Attend school normally (with support during treatment)
• Play sports and be physically active (with one kidney)
• Have children of their own in the future (fertility usually preserved)
• Live a full, normal life

Living with One Kidney

Important advice for children with one kidney:

✅ Safe Activities:

• Swimming, running, cycling, most sports
• Normal school activities
• Normal diet (no special restrictions)

⚠️ Precautions:

• Avoid contact sports with high risk of kidney injury (rugby, boxing, martial arts) – discuss with doctor
• Drink plenty of water to keep kidney healthy
• Tell doctors your child has one kidney (important for any future medications or surgery)
• Regular blood pressure checks (at least yearly)

Questions Parents Often Ask

Q: Did I do something to cause this?
A: No. Wilms' tumour is not caused by anything you did or didn't do during pregnancy or childhood. It occurs due to changes in cells before birth that we cannot prevent.

Q: Is it hereditary? Will my other children get it?
A: Most cases are not inherited. Only 1-2% of Wilms' tumours run in families. Unless your child has a genetic syndrome (your doctor will tell you), your other children are not at increased risk.

Q: Will my child's hair grow back after chemotherapy?
A: Yes. Hair loss from chemotherapy is temporary. Hair usually starts growing back 3-6 months after chemotherapy finishes, though it may be a different colour or texture initially.

Q: Can my child go to school during treatment?
A: This depends on how your child feels and their blood counts (immune system). During intensive chemotherapy, children may need to stay home to avoid infections. Your child's hospital school teacher will provide education support. Many children return to school part-time between chemotherapy cycles.

Q: What if the cancer comes back?
A: If Wilms' tumour returns (recurs), it is usually within the first 2 years after treatment. Recurrent Wilms' tumour can still be treated successfully in about half of children, using more intensive chemotherapy, surgery, and radiotherapy. Your medical team will discuss the best options if this happens.

Support and Resources

• Paediatric Oncology Team: Specialist doctors, nurses, and play therapists supporting your child
• Childhood Cancer Charities: Organisations like Young Lives vs Cancer, CLIC Sargent (UK) provide practical and emotional support
• Hospital School Teachers: Continue education during treatment
• Psychologists: Support for child and family coping with cancer diagnosis

---

13. Examination Focus

High-Yield MRCPCH Examination Topics

Clinical Examination Station

Scenario: "Examine this 3-year-old child's abdomen. The parents are concerned about a lump."

Examination Approach:

1. Introduction, consent, positioning, exposure
2. Inspection: Abdominal asymmetry (flank fullness)
3. Palpation: Large, smooth, unilateral flank mass, does not cross midline
4. Ballotement: May be ballotable (retroperitoneal)
5. Complete exam: Examine contralateral side, check genitalia (hypospadias?), eyes (aniridia?), measure limbs (hemihypertrophy?)
6. Blood pressure: Essential (hypertension in 25%)

Presentation: "This 3-year-old child has a large, smooth, non-tender mass arising from the right flank, which does not cross the midline and is ballotable. I would like to check the child's blood pressure and examine the eyes for aniridia. My differential diagnosis is a renal mass, most likely Wilms' tumour."

Expected Questions:

• "What features distinguish this from neuroblastoma?" → Does not cross midline, child appears well, urinary catecholamines normal
• "What investigations would you arrange?" → USS abdomen (first-line), urinary VMA/HVA, FBC/U&Es, CXR
• "What syndromes are associated with Wilms' tumour?" → WAGR, Beckwith-Wiedemann, Denys-Drash

Data Interpretation Station

Scenario: "A 4-year-old presents with abdominal mass. Here are the investigation results. What is your interpretation?"

Given Data:

• USS abdomen: 10cm solid intrarenal mass, right kidney
• Urinary VMA: 15 μmol/mmol creatinine (normal less than 25)
• Urinary HVA: 20 μmol/mmol creatinine (normal less than 35)
• FBC: Hb 110 g/L, WCC 8.0, Platelets 350
• U&Es: Normal
• BP: 130/85 mmHg (> 95th centile for age)

Interpretation:

• Diagnosis: Wilms' tumour (nephroblastoma)
• Reasoning:
  • Intrarenal solid mass (favours Wilms' over neuroblastoma)
  • Normal urinary catecholamines (rules out neuroblastoma)
  • Hypertension (renin-mediated, seen in 25% of Wilms')
• Next steps: CT abdomen/chest for staging, MDT referral to paediatric oncology

Communication Station

Scenario: "You are the paediatric registrar. A 3-year-old has been diagnosed with Wilms' tumour after presenting with an abdominal mass. The imaging shows Stage II disease (tumour extends through renal capsule but completely resectable). Explain the diagnosis and treatment plan to the parents."

Structure:

1. Setup: Quiet room, both parents present, introduce self, check understanding so far
2. Diagnosis: "The scans show a tumour in your child's kidney called Wilms' tumour. It's a type of cancer, but I want to reassure you immediately – this is one of the most curable childhood cancers."
3. Treatment Plan:
   • "We use a combination of treatments: chemotherapy (medicine), surgery (remove the affected kidney), and sometimes radiotherapy (X-rays)."
   • "Your child will have chemotherapy for 4-6 weeks first to shrink the tumour, then surgery to remove the kidney, then more chemotherapy."
4. Prognosis: "With this stage of disease, more than 90% of children are cured. Treatment is very effective."
5. One Kidney: "Children live completely normal lives with one kidney. It grows larger and does the work of two."
6. Questions: Invite questions, provide written information, introduce to specialist nurse
7. Support: "Our team includes doctors, nurses, play therapists, psychologists – we will support you every step of the way."

Viva Voce Questions and Model Answers

Question 1: "What is the genetic basis of Wilms' tumour?"

Model Answer: "Wilms' tumour arises from disrupted kidney development due to genetic alterations affecting tumour suppressor genes, primarily:

1. WT1 gene (11p13): Encodes a transcription factor essential for kidney and gonad development. Germline WT1 mutations cause WAGR syndrome, Denys-Drash syndrome, and Frasier syndrome. Somatic WT1 mutations found in 10-20% of sporadic Wilms' tumours. [5]

2. WT2 locus (11p15): Contains imprinted genes (IGF2, H19, CDKN1C). Loss of imprinting (LOI) leads to biallelic IGF2 expression, promoting growth. This underlies Beckwith-Wiedemann syndrome and is found in 70% of Wilms' tumours. [15]

3. Other genes: CTNNB1 (β-catenin/Wnt pathway), TP53 (anaplastic histology), WTX (X-linked tumour suppressor).

The two-hit hypothesis applies: Germline mutation (first hit) + somatic mutation (second hit) → tumour formation. This explains earlier age at diagnosis and bilateral disease in syndromic cases."

Question 2: "Why does the SIOP protocol use pre-operative chemotherapy whereas COG does not?"

Model Answer: "The two protocols reflect different philosophies with equivalent outcomes:

SIOP (Europe/UK) – Pre-operative chemotherapy:

• Rationale: Shrink tumour → easier, safer surgery → reduced rupture rate (5% vs 15%) [8]
• Advantages: Smaller surgical field, reduced Stage III disease, assess chemotherapy response
• Disadvantages: Altered histology (cannot assess true biology), may treat benign lesions

COG (North America) – Upfront surgery:

• Rationale: Accurate histology-first approach guides therapy
• Advantages: Definitive diagnosis, avoid chemotherapy for benign lesions, molecular markers from fresh tissue
• Disadvantages: Larger surgery, higher rupture risk

Evidence: Both achieve > 90% cure rates, demonstrating two valid approaches. Choice depends on regional practice. UK follows SIOP protocol."

Question 3: "A child with Stage III Wilms' tumour has completed chemotherapy and surgery but develops new lung nodules 12 months later. What is your management?"

Model Answer: "This represents relapsed Wilms' tumour (pulmonary recurrence). Management:

Investigations:

1. CT chest – characterise nodules
2. CT abdomen – assess for local recurrence
3. Biopsy (if safe) – confirm relapse vs second malignancy
4. FBC, U&Es, LFTs – baseline for salvage therapy

Treatment:

1. MDT discussion – paediatric oncology, thoracic surgery, radiology
2. Salvage chemotherapy – intensive regimen (e.g., ifosfamide, carboplatin, etoposide – ICE protocol)
3. Surgery – lung metastasectomy if limited, resectable disease
4. Radiotherapy – whole-lung irradiation for bilateral/multiple nodules
5. Psychosocial support – devastating diagnosis, involve family support team

Prognosis: Relapsed favourable-histology Wilms' has 50-60% salvage rate with aggressive multimodal therapy. Early detection through surveillance imaging is critical."

Question 4: "What are the long-term complications of Wilms' tumour treatment, and how do you monitor for them?"

Model Answer: "Wilms' tumour survivors require lifelong surveillance for treatment-related late effects:

1. Chronic Kidney Disease (single kidney, chemotherapy, radiation):

• Monitoring: Annual BP, urinalysis, serum creatinine, eGFR
• Management: Nephrology referral if eGFR less than 60, avoid nephrotoxins, BP control

2. Cardiovascular Disease (doxorubicin cardiotoxicity):

• Monitoring: Echocardiography at end of treatment, then 2-yearly lifelong
• Management: Cardiology referral if LVEF reduced, heart failure therapy

3. Scoliosis (flank radiotherapy – asymmetric spinal growth):

• Monitoring: Annual clinical examination, spine X-rays if scoliosis detected
• Management: Orthopaedic referral, bracing or surgery if severe

4. Second Malignancies (2-3% at 20 years):

• Monitoring: Clinical vigilance, age-appropriate screening (mammography if chest radiotherapy)
• Management: Early detection and treatment

5. Infertility (rare with standard protocols):

• Monitoring: Discuss at transition to adult care
• Management: Fertility assessment, assisted reproduction if needed

6. Psychosocial (cancer survivorship):

• Monitoring: Psychological assessment, educational support
• Management: Psychology referral, school liaison

Follow-up schedule: 3-monthly (years 0-5), 6-monthly (years 5-10), annually (> 10 years), transition to adult late-effects clinic."

---

14. References

Primary Sources

1. Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol. 2015;33(27):2999-3007. doi:10.1200/JCO.2015.62.1888

2. Davidoff AM. Wilms Tumor. Adv Pediatr. 2012;59(1):247-267. doi:10.1016/j.yapd.2012.04.001

3. Hamilton TE, Kieran K, Billings SD, et al. Bilateral Wilms Tumor: A Review of Treatment Paradigms. Pediatr Blood Cancer. 2019;66(12):e27975. doi:10.1002/pbc.27975

4. Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of Doxorubicin from the Treatment of Stage II-III, Intermediate-Risk Wilms' Tumour (SIOP WT 2001): An Open-Label, Non-Inferiority, Randomised Controlled Trial. Lancet. 2015;386(9999):1156-1164. doi:10.1016/S0140-6736(15)60065-0

5. Royer-Pokora B, Weirich A, Schumacher V, et al. Clinical Relevance of Mutations in the Wilms Tumor Suppressor 1 Gene WT1 and the Cadherin-Associated Protein β1 Gene CTNNB1 for Patients with Wilms Tumors: Results of Long-Term Surveillance of 71 Patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer. 2008;113(5):1080-1089. doi:10.1002/cncr.23672

6. Scott RH, Murray A, Baskcomb L, et al. Stratification of Wilms Tumor by Genetic and Epigenetic Analysis. Oncotarget. 2012;3(3):327-335. doi:10.18632/oncotarget.468

7. Meisel JA, Guthrie KA, Breslow NE, et al. Significance and Management of Computed Tomography-Detected Pulmonary Nodules: A Report from the National Wilms Tumor Study Group. Int J Radiat Oncol Biol Phys. 1999;44(3):579-585. doi:10.1016/s0360-3016(99)00008-4

8. Graf N, van Tinteren H, Bergeron C, et al. Characteristics and Outcome of Stage II and III Non-Anaplastic Wilms' Tumour Treated According to the SIOP Trial and Study 93-01. Eur J Cancer. 2012;48(17):3240-3248. doi:10.1016/j.ejca.2012.06.007

9. Fischbach BV, Trout KL, Lewis J, et al. WAGR Syndrome: A Clinical Review of 54 Cases. Pediatrics. 2005;116(4):984-988. doi:10.1542/peds.2004-0467

10. Wilde JCH, Aronson DC, Sznajder B, et al. Nephron-Sparing Surgery (NSS) for Unilateral Wilms Tumor: The SIOP 6 Experience. Pediatr Blood Cancer. 2014;61(12):2175-2179. doi:10.1002/pbc.25185

11. Stiller CA, Parkin DM. Geographic and Ethnic Variations in the Incidence of Childhood Cancer. Br Med Bull. 1996;52(4):682-703. doi:10.1093/oxfordjournals.bmb.a011577

12. Mussa A, Ferrero GB, Ceoloni B, et al. Neonatal Hepatoblastoma in a Newborn with Severe Phenotype of Beckwith-Wiedemann Syndrome. Eur J Pediatr. 2011;170(11):1407-1411. doi:10.1007/s00431-011-1451-1

13. Jeanpierre C, Denamur E, Henry I, et al. Identification of Constitutional WT1 Mutations, in Patients with Isolated Diffuse Mesangial Sclerosis, and Analysis of Genotype/Phenotype Correlations by Use of a Computerized Mutation Database. Am J Hum Genet. 1998;62(4):824-833. doi:10.1086/301806

14. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic Rests, Nephroblastomatosis, and the Pathogenesis of Wilms' Tumor. Pediatr Pathol. 1990;10(1-2):1-36. doi:10.3109/15513819009067094

15. Steenman MJ, Rainier S, Dobry CJ, et al. Loss of Imprinting of IGF2 Is Linked to Reduced Expression and Abnormal Methylation of H19 in Wilms' Tumour. Nat Genet. 1994;7(3):433-439. doi:10.1038/ng0794-433

16. Dome JS, Perlman EJ, Graf N. Risk Stratification for Wilms Tumor: Current Approach and Future Directions. Am Soc Clin Oncol Educ Book. 2014:215-223. doi:10.14694/EdBook_AM.2014.34.215

17. Shamberger RC, Ritchey ML, Haase GM, et al. Intravascular Extension of Wilms Tumor. Ann Surg. 2001;234(1):116-121. doi:10.1097/00000658-200107000-00017

18. Raval MV, Bilimoria KY, Bentrem DJ, et al. Nodal Evaluation in Wilms' Tumour: Analysis of the National Cancer Data Base. Ann Surg. 2010;251(3):559-565. doi:10.1097/SLA.0b013e3181c7e7ff

19. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369(9579):2106-2120. doi:10.1016/S0140-6736(07)60983-0

20. Riccabona M. Imaging of Renal Tumours in Infancy and Childhood. Eur Radiol. 2003;13 Suppl 4:L116-129. doi:10.1007/s00330-003-1892-8

21. Grundy PE, Breslow NE, Li S, et al. Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312-7321. doi:10.1200/JCO.2005.01.2799

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines. Management protocols (SIOP vs COG) may vary by region; follow your institution's protocol.